Back to top
more

TransMedics Group (TMDX)

(Delayed Data from NSDQ)

$85.50 USD

85.50
1,143,210

-0.85 (-0.98%)

Updated Nov 7, 2024 04:00 PM ET

After-Market: $85.50 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 26% (63 out of 251)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Dorsata's Alliance on Adnexal Masses to Support Aspira Stock

by Zacks Equity Research

AWH's partnership with Dorsata is set to help with the adnexal masses diagnosis and treatment.

Favorable Clinical Results for HYLA Sensor Might Boost Inspira Stock

by Zacks Equity Research

IINN plans to report clinical results for its new HYLA blood sensor in open-heart surgery patients in the fourth quarter of 2024.

Cellectar Biosciences to Present at IWWM Featuring Iopofosine I 131

by Zacks Equity Research

CLRB announces two presentations featuring its Iopofosine I 131 at the 12th IWWM, in Prague. Jorge Castillo will be the presenter.

Should You Consider Retaining Bruker Stock in Your Portfolio Now?

by Zacks Equity Research

BRKR's robust growth potential across its major segments is encouraging. Yet, macro woes and competitive pressure can pose challenges.

TransMedics (TMDX) Is Up 3.16% in One Week: What You Should Know

by Zacks Equity Research

Does TransMedics (TMDX) have what it takes to be a top stock pick for momentum investors? Let's find out.

Market Share Gains Aid Zimmer Biomet Stock Amid Cost Pressure

by Zacks Equity Research

In terms of Persona cementless Knee, ZBH is currently witnessing strong uptake of the cementless platform Persona OsseoTi.

New Launches Support Tandem Diabetes Stock Despite Macro Concerns

by Zacks Equity Research

The latest addition to TNDM's pump platform portfolio, Tandem Mobi, is leading the way in creating a whole new category of devices for insulin therapy.

Phibro Q4 Earnings and Revenues Beat, Operating Margin Down

by Zacks Equity Research

PAHC's impressive fourth-quarter fiscal 2024 results can be attributed to the Animal Health segment's robust performance.

Neogen Suffers From Competitive Pressure, Macroeconomic Woes

by Zacks Equity Research

NEOG faces intense competition, which could affect the marketability and profitability of its products.

ABT Expands Pure Bliss Line of Products for Advanced Infant Nutrition

by Zacks Equity Research

Abbott announces the expansion of its Pure Bliss by Similac line of products for infant nutrition with Organic and Organic A2 Milk infant formulas.

Is It Apt to Hold Globus Medical Stock in Your Portfolio Now?

by Zacks Equity Research

GMED's robust prospects in the musculoskeletal field and the synergies from the NuVasive merger bode well. Yet, macroeconomic issues can affect performance.

Quest Diagnostics Expands in North America With New Acquisition

by Zacks Equity Research

DGX acquires 100% of LifeLabs from OMERS, at approximately $1 billion. It will help LifeLabs to improve healthcare for Canadians.

Reasons to Retain QIAGEN Stock in Your Portfolio Now

by Zacks Equity Research

Investors remain optimistic about QGEN due to its progress in test menu expansion and impressive prospects within its molecular diagnostics segments.

Ekso Bionics (EKSO) Addressable Market to Grow on CMS Update

by Zacks Equity Research

The CMS reimbursement is pivotal for Ekso Bionics (EKSO), as it opens up substantial opportunities in a market where cost has often been a barrier to access

Santanu Roy headshot

Take the Zacks Approach to Beat the Markets: Vista Gold, TransMedics, Accenture in Focus

by Santanu Roy

Last week, our time-tested methodologies served investors well in navigating the market. Check out some of our achievements from the past three months.

Reasons to Retain ICON (ICLR) Stock in Your Portfolio Now

by Zacks Equity Research

Investors remain optimistic about ICON (ICLR) due to its commitment to patient access and impressive strategic pacts.

SI-BONE (SIBN) Receives FDA Nod for Its TNT Implant System

by Zacks Equity Research

SI-BONE (SIBN) receives FDA 510(k) clearance for its iFuse TORQ TNT implant system, followed by a Breakthrough Device Designation award by the FDA.

Microbot Medical (MBOT) Inks New Phase 2 Agreement for LIBERTY

by Zacks Equity Research

Microbot Medical (MBOT) signs a Phase 2 collaboration agreement with Corewell Health to advance remote telesurgery for endovascular procedures using LIBERTY.

Henry Schein (HSIC) Hurt by Macroeconomic Woes, Cyber Attacks

by Zacks Equity Research

With sustained macroeconomic pressure, Henry Schein (HSIC) struggles to keep in check its cost of revenues and operating expenses.

Should You Hold Labcorp (LH) Stock in Your Portfolio Now?

by Zacks Equity Research

Labcorp's (LH) slew of partnerships and acquisitions and robust efforts in high-growth areas bode well.

Reasons to Retain Bio-Rad (BIO) Stock in Your Portfolio Now

by Zacks Equity Research

Bio-Rad's (BIO) robust digital PCR business and Clinical Diagnostics segments raise optimism. However, macro issues raise concerns.

Globus Medical's (GMED) Lateral Interbody Portfolio Gets New Launch

by Zacks Equity Research

Globus Medical's (GMED) lateral interbody portfolio gets its first commercial product launch with ADIRA XLIF Plate System.

Reasons to Retain Thermo Fisher (TMO) in Your Portfolio Now

by Zacks Equity Research

Strategic alliances and impressive product launches bode well for Thermo Fisher (TMO).

Omnicell (OMCL) Introduces Central Med Automation Service

by Zacks Equity Research

Omnicell (OMCL) has come up with a subscription-based solution named Central Med Automation Service. The solution is expected to improve inventory visibility, scalability and patient safety.

Medtronic (MDT) Q1 Earnings Beat, Fiscal 2025 View Narrowed

by Zacks Equity Research

Medtronic (MDT) reports broad-based growth across all major segments, with strong gains in Cardiac Rhythm & Heart Failure, Structural Heart & Aortic, Cranial & Spinal Technologies and Diabetes businesses.